JP5542430B2 - 神経変性疾患の治療 - Google Patents

神経変性疾患の治療 Download PDF

Info

Publication number
JP5542430B2
JP5542430B2 JP2009501780A JP2009501780A JP5542430B2 JP 5542430 B2 JP5542430 B2 JP 5542430B2 JP 2009501780 A JP2009501780 A JP 2009501780A JP 2009501780 A JP2009501780 A JP 2009501780A JP 5542430 B2 JP5542430 B2 JP 5542430B2
Authority
JP
Japan
Prior art keywords
selenate
tau
pharmaceutically acceptable
acceptable salt
pp2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009501780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532340A (ja
JP2009532340A5 (https=
Inventor
クリストファー ホベンス
ニオール コーコラン
Original Assignee
ベラコル セラピューティクス プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベラコル セラピューティクス プロプライエタリー リミテッド filed Critical ベラコル セラピューティクス プロプライエタリー リミテッド
Publication of JP2009532340A publication Critical patent/JP2009532340A/ja
Publication of JP2009532340A5 publication Critical patent/JP2009532340A5/ja
Application granted granted Critical
Publication of JP5542430B2 publication Critical patent/JP5542430B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2009501780A 2006-03-29 2007-03-29 神経変性疾患の治療 Expired - Fee Related JP5542430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
US60/787,240 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2009532340A JP2009532340A (ja) 2009-09-10
JP2009532340A5 JP2009532340A5 (https=) 2010-05-13
JP5542430B2 true JP5542430B2 (ja) 2014-07-09

Family

ID=38540722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009501780A Expired - Fee Related JP5542430B2 (ja) 2006-03-29 2007-03-29 神経変性疾患の治療

Country Status (14)

Country Link
US (2) US8920851B2 (https=)
EP (1) EP2004204B1 (https=)
JP (1) JP5542430B2 (https=)
KR (1) KR101451439B1 (https=)
CN (1) CN101478977B (https=)
AU (1) AU2007231547B2 (https=)
BR (1) BRPI0709033A2 (https=)
CA (1) CA2644441C (https=)
DK (1) DK2004204T3 (https=)
ES (1) ES2394348T3 (https=)
MX (1) MX2008012479A (https=)
NZ (2) NZ596244A (https=)
RU (1) RU2489155C2 (https=)
WO (1) WO2007109851A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
MX2008012479A (es) 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
US20080107755A1 (en) * 2006-04-24 2008-05-08 Alltech, Inc. Methods and compositions for altering cell function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
WO2009065596A2 (en) * 2007-11-22 2009-05-28 Develogen Aktiengesellschaft Use of mnk inhibitors for the treatment of alzheimer's disease
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
CA2836503C (en) 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
AU2016235685B2 (en) * 2015-03-26 2019-04-18 Shanghai Auzone Biological Technology Co., Ltd. Method of diagnosis or treatment of neurological disorders with p75ECD and/or p75
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
KR102846956B1 (ko) * 2018-06-29 2025-08-14 리주베나떼 바이오메드 엔브이 노화-관련 질환 및/또는 퇴행성 질환에 사용하는 약제학적 결합물
JP7518852B2 (ja) 2019-03-26 2024-07-18 シアー， インコーポレイテッド 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPH04247033A (ja) 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5695752A (en) * 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) * 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) * 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
BRPI0409914A (pt) 2003-04-30 2006-04-25 Inst For Pharm Discovery Inc ácidos carboxìlicos substituìdos
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) * 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
US20080004255A1 (en) * 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CN101073584B (zh) 2005-10-14 2012-10-10 全面技术公司 改变细胞功能的方法和组合物
MX2008012479A (es) 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
EP2004205A4 (en) 2006-03-29 2010-06-09 Velacor Therapeutics Pty Ltd INORGANIC SELEN FOR THE TREATMENT OF GOOD TUMORS

Also Published As

Publication number Publication date
AU2007231547B2 (en) 2012-07-12
US20090169649A1 (en) 2009-07-02
KR101451439B1 (ko) 2014-10-16
EP2004204A1 (en) 2008-12-24
NZ596244A (en) 2013-05-31
US20140141104A1 (en) 2014-05-22
AU2007231547A1 (en) 2007-10-04
RU2008142514A (ru) 2010-05-10
EP2004204B1 (en) 2012-09-12
JP2009532340A (ja) 2009-09-10
NZ571835A (en) 2011-11-25
CN101478977A (zh) 2009-07-08
CN101478977B (zh) 2013-03-27
EP2004204A4 (en) 2010-06-02
KR20090015038A (ko) 2009-02-11
CA2644441A1 (en) 2007-10-04
MX2008012479A (es) 2009-08-13
US8920851B2 (en) 2014-12-30
CA2644441C (en) 2014-09-09
ES2394348T3 (es) 2013-01-30
DK2004204T3 (da) 2013-01-07
RU2489155C2 (ru) 2013-08-10
WO2007109851A1 (en) 2007-10-04
BRPI0709033A2 (pt) 2011-06-21

Similar Documents

Publication Publication Date Title
JP5542430B2 (ja) 神経変性疾患の治療
JP5736421B2 (ja) 生理学的過程の調節およびこれに有用な薬剤
Melis et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
Lubitz et al. High dietary advanced glycation end products are associated with poorer spatial learning and accelerated Aβ deposition in an Alzheimer mouse model
JP5616631B2 (ja) 細胞機能を変化させるための方法および組成物
Yabuki et al. Oral L-citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection
Sharma et al. Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats
PT2282779E (pt) Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular
Chu et al. Induction of autophagy by a novel small molecule improves aβ pathology and ameliorates cognitive deficits
Malavolta et al. Trace elements and minerals in health and longevity
Bignante et al. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models
Morigaki et al. Dopamine-induced changes in Gαolf protein levels in striatonigral and striatopallidal medium spiny neurons underlie the genesis of L-DOPA-induced dyskinesia in parkinsonian mice
JP6928450B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
US9072730B2 (en) Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
Zhang et al. TMEM175 downregulation participates in impairment of the autophagy related lysosomal dynamics following neonatal hypoxic‐ischemic brain injury
WO2008119109A1 (en) Treatment of neurological disorders
US20160022714A1 (en) O-glcnacylation treatment for ischemic brain injury
Park et al. Protective effects of phosphodiesterase 5 inhibitor, mirodenafil, on traumatic brain injury-induced neuron death
Munzuroğlu et al. Nitric oxide plays a role in anxiety-and depression-like behaviors induced by sodium metabisulfite intake in rats
CN119055674B (zh) 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用
Suliburk et al. Time-Dependent Aggravation or Attenuation of Lipopolysaccharide-Induced Gastric Injury by Nitric Oxide Synthase Inhibition1
Fletcher Investigating Chondroitin Sulphate Proteoglycans as a Therapeutic Target for Parkinson's disease
Zhao Role of TRPM2 in Autophagy of Vascular Smooth Muscle Cells and Cardiomyocytes
Challasivakanaka Regulation Of Proline-Directed Phosphorylation Site, Threonine 53 On Dopamine Transporter
Shao See Into The Future Understanding the acute and progressive pathophysiology of oxygen induced retinopathy for potential therapeutic development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140507

R150 Certificate of patent or registration of utility model

Ref document number: 5542430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees